vascular endothelial growth factor , VEGF (skrót)

One study suggested a possible role for vascular endothelial growth factor.

An association with vascular endothelial growth factor has been observed.

The role of vascular endothelial growth factor in pathological angiogenesis.

It is an inhibitor of vascular endothelial growth factor.

Decreased expression is also observed in cells treated with vascular endothelial growth factor.

Vascular endothelial growth factor A has been shown to interact with:

One drug is gene therapy to produce a protein called vegF, for vascular endothelial growth factor.

This communication takes place, in part, through the secretion of angiogenesis factors such as vascular endothelial growth factor.

It has been shown to reduce angiogenesis and the expression of vascular endothelial growth factor in some tissue cultures.

Exogenous leptin can promote angiogenesis by increasing vascular endothelial growth factor levels.

The drug is an antibody that blocks vascular endothelial growth factor, a protein instrumental in formation of blood vessels.

Vascular endothelial growth factor is a signal protein responsible for beginning the processes of vasculogenesis and angiogenesis.

Avastin blocks vascular endothelial growth factor, one of the most important proteins involved in spurring blood vessel formation.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

The substance, a protein called vascular endothelial growth factor, or vegf, is secreted by cells lining an artery.

Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression.

Other factors released include interleukin-15 and vascular endothelial growth factor (VEGF).

A striking exception was the family of vascular endothelial growth factors (VEGF).

This protein is called vascular endothelial growth factor (VEGF).

One phase in the growth of these blood vessels is the production of vascular endothelial growth factor, the body's response to injury and inflammation.

It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2).

Vascular endothelial growth factor D is elevated in the serum of patients with LAM.

Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist.

One class of drugs, called vascular endothelial growth factor inhibitors, for example, is designed to thwart the growth of abnormal blood vessels in the eye.

Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation.